Galectin Therapeutics Inc (OQ:GALT)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4960 Peachtree Industrial Blvd Ste 240
BERKELEY LAKE GA 30071-1580
Tel: N/A
Website: galectintherapeutics.com
IR: See website
<
Key People
Richard E. Uihlein
Chairman of the Board
Joel Lewis
President, Chief Executive Officer, Director
Jack W. Callicutt
Chief Financial Officer, Secretary
Harold H. Shlevin
Chief Operating Officer, Director
Eliezer Zomer
Executive Vice President - Manufacturing and Product Development
Adam E. Allgood
Executive Director of Clinical Development
Pol F. Boudes
Chief Medical Officer
J. Rex Horton
Executive Director - Regulatory Affairs and Quality Assurance
 
Business Overview
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Financial Overview
For the six months ended 30 June 2020, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 20% to $9.7M. Lower net loss reflects Other General and administrative decrease of 10% to $2.3M (expense), Stock-based Compensation in SGA decrease of 15% to $584K (expense), Interest income increase of 4% to $59K (income).
Employees: 7 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $117.22M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$17.74M as of Jun 30, 2020
Net annual income (TTM): -$17.75M as of Jun 30, 2020
Free cash flow (TTM): -$12.21M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 57,043,661 as of Aug 6, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.